Effects of Candesartan Cilexetil on Health-Related Quality of Life in Black Patients with Systemic Hypertension in the ABC Trial

Heart Disease

Volumn 2, Issue 6, 2000, Pages 400-406

  Zyczynski, Teresa M ^a   Leidy, Nancy Kline ^b   Kong, B Waine ^c   Helaszek, Carla T ^a   Michelson, Eric L ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c Association of Black Cardiologists   (United States)

Author keywords

Angiotensin II receptor blocker; Association of black cardiologists (ABC); Blacks; Candesartan cilexetil; Health related quality of life; Hypertension; The ABC trial

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; NEGRO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; QUALITY OF LIFE; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0034332570     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a meta-analysis of clinical trials. Am J Hypertens 1992;5:125-133.
2. Croog SH, Levine S, Sudilovsky A, et al. Sexual symptoms in hypertensive patients: a clinical trial of antihypertensive medications. Arch Intern Med 1988; 148:788-794.
3. DeForge BR, Stewart DL, DeVoe-Weston M, et al. The relationship between health status and blood pressure in urban African Americans. J Natl Med Assoc 1998;90:658-664.
4. Oparil S. Antihypertensive therapy-efficacy and quality of lite. N Engl J Med 1993;328:959-961.
5. Testa MA, Anderson RB, Nackley JF, et al, and the Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. N Engl J Med 1993;328:907-913.
6. Turner RR. Role of quality of life in hypertension therapy: implication for patient compliance. Cardiology 1992;80(Suppl 1)11-22.
7. Black HR. Will better tolerated anti-hypertensive agents improve blood pressure control? JNC VI revisited. Am J Hypertens 1999;12(12 Pt 3):225S-230S.
8. Williams GH. Assessing patient wellness: new perspectives on quality of life and compliance. Am J Hypertens 1998;11:186S-191S.
9. Glik DC, Steadman S, Michels P, et al. Antihypertensive regimen and quality of life in a disadvantaged population. J Fam Pract 1990;30:143-152.
10. Croog SH, Kong SB, Levine S, et al. The Black Hypertension Quality of Life Multicenter Trial Group. Hypertensive black men and women: quality of life and effects of antihypertensive medications. Arch Intern Med 1990;150:1733-1741.
11. The Association of Black Cardiologists (ABC) Candesartan Study Group. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis 2000;2:392-399.
12. Greenfield S, Rogers W, Mangotich M, et al. Outcomes of patients with hypertension and non-insulin dependent diabetes mellitus treated by different systems and specialties. JAMA 1995;274:1436-1444.
13. Lawrence WF, Fryback DG, Martin PA, et al. Health status and hypertension: a population-based study. J Clin Epidemiol 1996;49:1239-1245.
14. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;62:907-913.
15. Kong BW, Bean JA, Stephens D. Assessment of the Vital Signs Quality of Life Questionnaire in three studies on hypertension. J Hum Hypertens 1995;9:255-262.
16. Ware JE, Snow KK, Kosinski M, et al. .SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
17. Ware Je, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User Manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
18. Dexter PR, Stump TE, Tierney WM, et al. The psychometric properties of the SF-36 Health Survey among older adults in a clinical setting. J Clin Geropsychol 1996;2:225-237.
19. Kusek JW, Lee JY, Smith DE, et al, for the AASK Pilot Study Investigators. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996;17(Suppl 4):40S-46S.
20. Johnson PA, Goldman L, Orav EJ, et al. Comparison of the Medical Outcomes Study Short-Form 36-Item Health Survey in black patients and white patients with acute chest pain. Med Care 1995;33:145-160.
21. Kelso TM, Abou-Shala N, Heilker GM, et al. Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans. Am J Med Sci 1996;311:272-280.
22. Leidy NK, Chan K, Coughlin C. Is the Asthma Quality of Life Questionnaire (AQLQ) a useful measure in low-income asthmatics? Am Rev Resp Crit Care Med 1998;158:1082-1090.
23. Weinberger M, Oddone EZ, Samsa GP, et al. Are health-related quality-of-life measures affected by the mode of administration? J Clin Epidemiol 1996,49: 135-140.
24. Chambers JW, Kong BW. Assessing quality of life: construction and validation of a scale. In: Jones R (ed). Handbook of Test and Measurements for Black Populations. Hampton, VA: Cobb & Henry Publishers, 1996.
25. Kong BW, Clive J, Kong S. Quality of life as a vital sign. J Hum Hypertens 1990;4:121-123.
26. Bonomi AE, Legro MW, Leidy NK, et al. Maximizing quality in quality of life outcomes research: a multifaceted approach for clinical trials [abstract]. Qual Life Res 1998;7:574.
27. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-258.
28. National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes, NIH Publication No. 1998:98-4083.
29. Gleason PP, Schulz R. Assessing pharmacotherapy outcomes: a model for clinicians. Pharmacotherapy 1996;16:1142-1153.
30. Gregoire JP. Choice of initial antihypertensive medication and continuation of use. Can J Cardiol 1999;15(Suppl F):39F-41F.
31. Stason W. Compliance, quality of life, and cost-effectiveness. Curr Hypertens Rep 1999;1:471-474.
32. Grimm RH Jr, Grandits GA, Cutler JA, et al, for the TOMHS Research Group. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997;157:638-648.
33. Gibbs CR, Beevers DG, Lip GH. The management of hypertensive disease in black patients. QJM 1999;92:187-192.
34. Miller NH, Hill M, Kottke T, et al. The multilevel compliance challenge: recommendations for a call to action: A statement for healthcare professionals. Circulation 1997;95:1085-1090.